Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus AI (NASDAQ: TEM) will present six abstracts at the 2026 Connective Tissue Oncology Society Annual Meeting, November 18–21 in Seoul. The program includes three oral presentations and three posters on rare mesenchymal tumors, including sarcomas.
Topics include molecular biomarkers, tumor classification, treatment response and inherited genetic variant detection. The research draws on a de-identified data library that includes 45,085 real-world patients across 615 rare and ultra-rare cancer types.
Blood Cancer United launched REALworld: AML with Rally Foundation for Childhood Cancer Research to support research into pediatric acute myeloid leukemia. The initiative aims to build a dataset from patient health records to inform research and future clinical trials. Tempus (NASDAQ: TEM) is providing technology, including its Olivia app, which helps participating families organize and understand health records and receive educational information.
Families can currently contribute records from children living with or in remission from pediatric AML. The project expects to include records from children who have died in the near future. Over time, the data may support comparisons between investigational treatments and prior standard treatment, when scientifically and regulatorily appropriate. The initiative is part of Blood Cancer United's Dare to Dream program.
SOTERIA Precision Medicine Foundation announced a collaboration with Tempus (NASDAQ: TEM) to provide cancer treatment insights for U.S. service members and veterans.
The collaboration supports SOTERIA's Cancer Hunt initiative, combining patient navigation with Tempus' genomic profiling and AI-enabled diagnostic platform to help identify targeted therapies and clinical trial opportunities. The organizations plan to continue streamlining molecular profiling and data integration across SOTERIA's patient cohort to support precision oncology research and care pathways.
Tempus AI (TEM) reported third-quarter 2026 revenue of $411.5 million, up 23% from the same period in 2025.
Diagnostics revenue rose 20% to $303.5 million, while Data and Applications revenue increased 33% to $108.1 million. Oncology test volume grew 32%. Gross profit increased 27% to $266.7 million. Net loss narrowed to $14.9 million from $80.0 million, including $42.8 million in unrealized securities gains. Adjusted EBITDA rose to $25.6 million from $1.5 million.
Tempus raised its 2026 revenue outlook to $1.60–$1.605 billion and maintained expected adjusted EBITDA of approximately $65 million. October agreements cover oncology data licensing to BMS for up to $137.5 million and Alzheimer's or dementia data licensing to BMS and Pathos for $55 million, each over five years. The pending Personalis acquisition cleared regulatory review; a shareholder approval meeting is planned for November 30, 2026.
Tempus AI (NASDAQ: TEM) received European Union IVDR certification for its xR RNA sequencing assay as a Class C diagnostic device.
The certification covers Tempus’ quality management system for next-generation sequencing devices used in cancer genomic profiling to support clinical management. xR detects gene rearrangements and specific splice variants in solid tumor tissue. Certification supports continued EU access beyond 2028, the transition deadline for eligible legacy Class C devices, and gives biopharma partners an IVDR-certified testing platform to support clinical studies.
Tempus AI (TEM) signed a multi-year agreement for Bristol Myers Squibb (BMY) to license its oncology data through 2031. The agreement covers de-identified data combining multiple types of information to support biological and clinical insights, drug target discovery and therapeutic development across BMS’s oncology portfolio.
BMS will also gain access to Tempus’ Lens Platform, where researchers can train and run AI models using de-identified data and dedicated computing infrastructure. The agreement expands an existing relationship involving AI and real-world data for clinical trial design in oncology and neuroscience.
Pathos AI announced multi-year collaborations with Bristol Myers Squibb (BMY) and Tempus AI (TEM) to advance drug development for neurological conditions.
Tempus will build a de-identified dataset tracking outcomes over time for hundreds of thousands of patients with neurological conditions. Pathos will license it under a five-year, $55 million agreement and apply its Foundry AI platform to study disease biology and inform clinical-trial design, beginning with Alzheimer’s disease and other neurological conditions.
Bristol Myers Squibb leads Pathos’s Series E financing and gains multi-year, non-exclusive access to Foundry across its broader research and development portfolio, plus three-year exclusive rights to support neuroscience development programs. Bristol Myers Squibb aims to use the platform and dataset to better understand disease progression and design more precise trials.
Tempus AI (NASDAQ: TEM) presented study results showing greater than 80% sensitivity across all 12 biomarkers assessed in advanced lung cancer.
The multi-center analysis covered 60,459 advanced non-small cell lung cancer cases across 56,969 patients. Sensitivity, a measure of how often a test identifies biomarker-positive cases, exceeded 90% for several biomarkers. The panel uses routine hematoxylin and eosin pathology images to predict biomarker status. Results were presented at the ESMO Congress 2026 in Madrid.
The panel remains in development. Tempus sees potential to help identify patients needing confirmatory biomarker testing. The study forms part of an ongoing collaboration with Pfizer addressing diagnostic barriers and supporting biomarker testing.
Tempus AI (TEM) will report its third-quarter 2026 financial results before U.S. markets open on November 2, 2026.
The quarter ended September 30, 2026. Founder and CEO Eric Lefkofsky and Chief Financial Officer Jim Rogers will lead a conference call and live audio webcast at 8:45 a.m. ET to discuss results and provide a business update. A recording will be available on the investor relations website after the call.
Tempus AI (TEM) subsidiary Ambry Genetics launched GenomeNext and GenomeReveal, a whole genome sequencing solution designed to help diagnose rare diseases.
GenomeNext uses a pangenome reference representing human genetic diversity, while GenomeReveal integrates RNA analysis to help interpret certain DNA findings. Testing includes Ambry’s Patient for Life program, which proactively reanalyzes patient data as knowledge of gene-disease relationships evolves. Ambry cited published research showing positive reclassifications in 5% of initially negative or uncertain exome sequencing cases; that finding is not a reported result for the newly launched tests.